Skip to main content
. 2018 Jul 25;3(14):e120422. doi: 10.1172/jci.insight.120422

Figure 6. Gene expression analysis of CSF1R, RUNX1, and IL-34 in refractory BRAF V600E melanoma patients.

Figure 6

(A) Scatter plots of log2 normalized read counts between pre- and posttreatment (resistant tumors) with RAF, MEK, or RAF/MEK inhibition in 9 BRAF V600E melanoma patients. (B) Changes in expression of CSF1R, IL-34, and RUNX1 while on treatment of MAPK pathway inhibitors (On-TX) or in refractory tumor samples compared with the pretreatment biopsies (Pre-TX) (1-way ANOVA).